louisakewell, Author at European Medical Journal - Page 90 of 153

EMJ

Study Shows Prostate Cancer Screening under Age of 55 May be of Limited Value

Barcelona, 14 November 2015: Mass prostate cancer (PSA) screening before the age of 55 may not have any benefit over screening starting after…

EMJ

Multiple Scientific Presentations at the Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies

San Francisco, November 14, 2015 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present 32 scientific presentations related to its…

EMJ

Drinking the EU Economy Dry: Experts Call for Action on the Crippling Socio-Economic Costs of Alcohol

November 12, 2015: Europe is the heaviest drinking region of the world, with consumption levels in some countries approximately twice the global average.

EMJ

Revolutionary Computer Program Diagnoses Cancer in 2 Days

NOVEL diagnostic technology based on advanced self-learning computer algorithms may identify the source of cancer in a patient with 85% certainty…

EMJ

Self-Propelled Microparticles Designed to Stop Bleeding

FIRST self-propelled particles capable of delivering coagulants against the flow of blood have been developed to treat severe bleeding…

EMJ

New German Data Show the Use of Endocuff Vision® May Improve Adenoma Detection Rates and Reduce Health System Costs

London, Wednesday 11 November 2015, 07:00 GMT: Norgine B.V. today announced new data showing that ENDOCUFF VISION®, a colonoscope device…

EMJ

Sherlock Holmes and the Assessment of Premature MI

At the 2015 ESC congress in London UK, Aegerion Pharmaceuticals organized a satellite symposium in which three expert witnesses were cross examined on…

Intelligent Application of Breast Cancer Trials Data in the Clinic

This meeting commenced with a talk from Prof Loibl on neoadjuvant and adjuvant strategies for HER2positive (human epidermal growth factor receptor…)

Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers

This engaging symposium focussed on the rationale and current evidence supporting the role for poly(adenosine diphosphate-ribose) polymerase (PARP)…

Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Results of a Randomised Phase III Trial (METEOR)

The METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma (RCC) was reported by Prof Choueiri at the European Cancer Congress…